Clients

Clients

Our clients are often emerging biopharma or device companies with a small product portfolio.  They engage Prescription Alliance to optimize their product’s launch into the US market.

Access & Availability Engagement

ACCESS & AVAILABILITY Engagement Example – Reimbursement of a pharmaceutical device product:

Situation: An international client who received a FDA 510K clearance (medical device) approval for a liquid/spray device combination in the US desired a pharmaceutical retail distribution strategy for their product. Payers previously viewed this product as a device covered under a medical benefit and not available or reimbursed through pharmacy methods.

Approach: Prescription Alliance’s strategy and implementation included engaging payers to view the combination liquid/device product as a new therapeutic category.   Over 50% of commercial payers added this new category as part of their pharmacy benefit.

Solution: Today, the product is reimbursed under the pharmacy benefit as a formulary item: Tier 3 covered and Tier 2 preferred agent…thereby reducing patient out of pocket expenses versus their medical benefit.

Availability Engagement

AVAILABILITY Engagement Example – Specialty distribution of an oncology product:

Situation: A US based company was not satisfied with their sub-optimal launch of an oncology product in a very crowded therapeutic class of four competitive product entrants.

Approach: The Prescription Alliance approach: Re-launch the product in the specialty distribution model. Develop a Hub central supply model for specialty distribution, as well as physician “buy & bill model.” Secondly re-price (increase) the product to match the specialty model.

Solution: The product re-launched as specialty drug.  It captured a higher market share and gained a better net revenue position within 6 months than its launch during the prior 24 months.

Access Engagement

ACCESS Engagement Example – Understand appropriate pricing, demand and probable payer formulary position for a new prescription chemical entity (NCE):

Situation: A US based research company in Phase III development plans to enter a market containing brands and generics.  The manufacturer was interested in possible payer price and access strategies.

Approach: The Prescription Alliance approach: Perform qualitative in-depth research using a panel of nationally recognized and experienced managed markets thought leaders.  Secondly, conducted quantitative research by using nationally recognized formulary and claims databases to extract and analyze data.

Solution: The company currently anticipates near term FDA approval and has used the Prescription Alliance developed roadmap (payer strategy, pricing and optimal access strategies) to secure additional investor interests and capital.

Global Clients